JP2008531704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2008531704A5 JP2008531704A5 JP2007558142A JP2007558142A JP2008531704A5 JP 2008531704 A5 JP2008531704 A5 JP 2008531704A5 JP 2007558142 A JP2007558142 A JP 2007558142A JP 2007558142 A JP2007558142 A JP 2007558142A JP 2008531704 A5 JP2008531704 A5 JP 2008531704A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- ribofuranosyl
- benzo
- dihydro
- tetraaza
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 150000001875 compounds Chemical class 0.000 claims 27
- -1 amino, aminocarbonyl Chemical group 0.000 claims 21
- 125000005843 halogen group Chemical group 0.000 claims 16
- 229910052739 hydrogen Inorganic materials 0.000 claims 15
- 239000001257 hydrogen Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 10
- 125000004442 acylamino group Chemical group 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 9
- 150000002431 hydrogen Chemical group 0.000 claims 9
- 150000001540 azides Chemical class 0.000 claims 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 125000000033 alkoxyamino group Chemical group 0.000 claims 6
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 claims 6
- 125000002349 hydroxyamino group Chemical group [H]ON([H])[*] 0.000 claims 6
- 238000000034 method Methods 0.000 claims 6
- 229910052757 nitrogen Inorganic materials 0.000 claims 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 229910052799 carbon Inorganic materials 0.000 claims 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 3
- 241000711549 Hepacivirus C Species 0.000 claims 3
- 241000700605 Viruses Species 0.000 claims 3
- 150000001413 amino acids Chemical class 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 239000000651 prodrug Substances 0.000 claims 3
- 229940002612 prodrug Drugs 0.000 claims 3
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 241000710781 Flaviviridae Species 0.000 claims 2
- 208000036142 Viral infection Diseases 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- NHKZSTHOYNWEEZ-AFCXAGJDSA-N taribavirin Chemical compound N1=C(C(=N)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NHKZSTHOYNWEEZ-AFCXAGJDSA-N 0.000 claims 2
- 229950006081 taribavirin Drugs 0.000 claims 2
- 230000009385 viral infection Effects 0.000 claims 2
- ICMNAHWBYQOWJO-NZQZLILVSA-N (2R,3R,4R,5R)-2-(11-fluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-3-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NCC(F)=C3)=C2C3=C1 ICMNAHWBYQOWJO-NZQZLILVSA-N 0.000 claims 1
- NSEYHMDNGSNOBQ-NZQZLILVSA-N (2R,3R,4R,5R)-2-(12-fluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-3-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NCC=C3F)=C2C3=C1 NSEYHMDNGSNOBQ-NZQZLILVSA-N 0.000 claims 1
- BLURITVAGFDMPS-NHULRPGXSA-N (2R,3R,4R,5R)-2-(3,5,7,9,10,12-hexazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-3-yl)-5-(hydroxymethyl)-3-methyloxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NNC=N3)=C2C3=C1 BLURITVAGFDMPS-NHULRPGXSA-N 0.000 claims 1
- IXXVTGLQEGPRLV-KNJXUWEQSA-N (2R,3R,4R,5R)-5-(hydroxymethyl)-3-methyl-2-(3,5,7,9,10-pentazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13),11-pentaen-3-yl)oxolane-3,4-diol Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NNC=C3)=C2C3=C1 IXXVTGLQEGPRLV-KNJXUWEQSA-N 0.000 claims 1
- IWUCXVSUMQZMFG-RGDLXGNYSA-N 1-[(2s,3s,4r,5s)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2,4-triazole-3-carboxamide Chemical compound N1=C(C(=O)N)N=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 IWUCXVSUMQZMFG-RGDLXGNYSA-N 0.000 claims 1
- OESHHJVQXYGCKW-FTTKWNSESA-N 11-amino-3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(N)=C3)=C2C3=C1 OESHHJVQXYGCKW-FTTKWNSESA-N 0.000 claims 1
- KYDZVISIOSNRMR-KXOWALFDSA-N 12-amino-3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-11-fluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(F)=C3N)=C2C3=C1 KYDZVISIOSNRMR-KXOWALFDSA-N 0.000 claims 1
- GLOQJXCSHIAUSF-ZCLWBALQSA-N 12-amino-3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaene-10-thione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=S)C=C3N)=C2C3=C1 GLOQJXCSHIAUSF-ZCLWBALQSA-N 0.000 claims 1
- RJFIQUNBXWRVTA-PMXXHBEXSA-N 12-amino-3-[(2R,3R,4R,5R)-4-hydroxy-5-(hydroxymethyl)-3-methoxyoxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound CO[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C=C3N)=C2C3=C1 RJFIQUNBXWRVTA-PMXXHBEXSA-N 0.000 claims 1
- ZKGVSTUMOHZOEQ-FRJWGUMJSA-N 12-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C1=C(C2=3)C(N)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O ZKGVSTUMOHZOEQ-FRJWGUMJSA-N 0.000 claims 1
- GRMYVLYSBJYKBE-ZCLWBALQSA-N 12-chloro-3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C=C3Cl)=C2C3=C1 GRMYVLYSBJYKBE-ZCLWBALQSA-N 0.000 claims 1
- SFQUTMMHSCDERR-YTUKDDMISA-N 2-(2'-methyl-β-d-ribofuranosyl)-2,9-dihydro-6h-2,3,5,6,9-pentaaza-benzo[cd]azulene-7,8-dione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2C(=O)NC3=C1 SFQUTMMHSCDERR-YTUKDDMISA-N 0.000 claims 1
- CFLGNWHWVWVTMA-JEGMJTAISA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaene-11-carbonitrile Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(C#N)=C3)=C2C3=C1 CFLGNWHWVWVTMA-JEGMJTAISA-N 0.000 claims 1
- TUOWVHKWPGTSGL-ZVTMDSFCSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaene-11-carboxamide Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(C(N)=O)=C3)=C2C3=C1 TUOWVHKWPGTSGL-ZVTMDSFCSA-N 0.000 claims 1
- IWPWLRDURFXKNV-KXOWALFDSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-11,12-difluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(F)=C3F)=C2C3=C1 IWPWLRDURFXKNV-KXOWALFDSA-N 0.000 claims 1
- ZKJIVMQMKMMFHI-FTTKWNSESA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-11-fluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C(F)=C3)=C2C3=C1 ZKJIVMQMKMMFHI-FTTKWNSESA-N 0.000 claims 1
- OAHNQJQLXDEFCL-ZCLWBALQSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-(hydroxyamino)-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C=C3NO)=C2C3=C1 OAHNQJQLXDEFCL-ZCLWBALQSA-N 0.000 claims 1
- GVOOKYOKQRCJFT-KHTZZEJVSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-(methoxyamino)-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C1=C(C2=3)C(NOC)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@]1(C)O GVOOKYOKQRCJFT-KHTZZEJVSA-N 0.000 claims 1
- IQDRYMACQDAPTL-KHTZZEJVSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-(methylamino)-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C1=C(C2=3)C(NC)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@]1(C)O IQDRYMACQDAPTL-KHTZZEJVSA-N 0.000 claims 1
- RZZYLGRBIREDSW-ZQEXUDESSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-fluoro-3,5,7,9,11-pentazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)N=C3F)=C2C3=C1 RZZYLGRBIREDSW-ZQEXUDESSA-N 0.000 claims 1
- WEBPMOZRCPJYAW-ZCLWBALQSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-fluoro-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C=C3F)=C2C3=C1 WEBPMOZRCPJYAW-ZCLWBALQSA-N 0.000 claims 1
- XEQDJLRBBKBFBE-ZCLWBALQSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-12-hydrazinyl-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)C=C3NN)=C2C3=C1 XEQDJLRBBKBFBE-ZCLWBALQSA-N 0.000 claims 1
- SPHINGCEMHXYKE-VHQAPHLWSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9,10,12-hexazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-11-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NNC(=O)N3)=C2C3=C1 SPHINGCEMHXYKE-VHQAPHLWSA-N 0.000 claims 1
- ODPUUCQVEIOVPK-AMJCQUEASA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9,11-pentazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-10-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)N=C3)=C2C3=C1 ODPUUCQVEIOVPK-AMJCQUEASA-N 0.000 claims 1
- XFYUUODDJHDVFN-ZQEXUDESSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9,11-pentazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8-tetraene-10,12-dione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)NC3=O)=C2C3=C1 XFYUUODDJHDVFN-ZQEXUDESSA-N 0.000 claims 1
- NIAJWNYWHQCZHB-YTUKDDMISA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9,12-pentazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-11-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NCC(=O)N3)=C2C3=C1 NIAJWNYWHQCZHB-YTUKDDMISA-N 0.000 claims 1
- XUJHVFLLGKRHTE-ZCLWBALQSA-N 3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraene-10,12-dione Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CN=C2NC(=O)CC3=O)=C2C3=C1 XUJHVFLLGKRHTE-ZCLWBALQSA-N 0.000 claims 1
- IQTNLLIVXRSHGW-YTUKDDMISA-N 9-amino-2-(2'-methyl-β-d-ribofuranosyl)-2,6-dihydro-2,3,5,6,8-pentaaza-benzo[cd]azulen-7-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2N=C(N)C3=C1 IQTNLLIVXRSHGW-YTUKDDMISA-N 0.000 claims 1
- YDTPSIYKHMTGKX-PZTHBURQSA-N 9-amino-2-(2'-methyl-β-d-ribofuranosyl)-2,6-dihydro-2,3,5,6-tetraaza-benzo[cd]azulen-7-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2C=C(N)C3=C1 YDTPSIYKHMTGKX-PZTHBURQSA-N 0.000 claims 1
- YCXPYXMDZXJQKB-QTDMDRALSA-N 9-carbamoyl-2-(2'-methyl-β-d-ribofuranosyl)-2,6-dihydro-2,3,5,6-tetraaza-benzo[cd]azulen-7-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2C=C(C(N)=O)C3=C1 YCXPYXMDZXJQKB-QTDMDRALSA-N 0.000 claims 1
- JKGHPHSYUAVDSB-UIBBOPPKSA-N 9-cyano-2-(2'-methyl-β-d-ribofuranosyl)-2,6-dihydro-2,3,5,6-tetraaza-benzo[cd]azulen-7-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2C=C(C#N)C3=C1 JKGHPHSYUAVDSB-UIBBOPPKSA-N 0.000 claims 1
- CDWPLWQNOLTUNM-PZTHBURQSA-N 9-iodo-2-(2'-methyl-β-d-ribofuranosyl)-2,6-dihydro-2,3,5,6-tetraaza-benzo[cd]azulen-7-one Chemical compound C[C@@]1(O)[C@H](O)[C@@H](CO)O[C@H]1N1N=C(C=NNC2=O)C3=C2C=C(I)C3=C1 CDWPLWQNOLTUNM-PZTHBURQSA-N 0.000 claims 1
- 101710088194 Dehydrogenase Proteins 0.000 claims 1
- GRSZFWQUAKGDAV-KQYNXXCUSA-N IMP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(O)=O)O[C@H]1N1C(NC=NC2=O)=C2N=C1 GRSZFWQUAKGDAV-KQYNXXCUSA-N 0.000 claims 1
- 102000016600 Inosine-5'-monophosphate dehydrogenases Human genes 0.000 claims 1
- 108050006182 Inosine-5'-monophosphate dehydrogenases Proteins 0.000 claims 1
- 102000006992 Interferon-alpha Human genes 0.000 claims 1
- 108010047761 Interferon-alpha Proteins 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108060004795 Methyltransferase Proteins 0.000 claims 1
- JIPYIHALDIWXLT-FPOOMLEOSA-N N-[3-[(2R,3R,4R,5R)-3,4-dihydroxy-5-(hydroxymethyl)-3-methyloxolan-2-yl]-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-12-yl]acetamide Chemical compound C1=C(C2=3)C(NC(=O)C)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@]1(C)O JIPYIHALDIWXLT-FPOOMLEOSA-N 0.000 claims 1
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 1
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 1
- 108091005804 Peptidases Proteins 0.000 claims 1
- 239000004365 Protease Substances 0.000 claims 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims 1
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical group N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 1
- 102000012479 Serine Proteases Human genes 0.000 claims 1
- 108010022999 Serine Proteases Proteins 0.000 claims 1
- 108010078233 Thymalfasin Proteins 0.000 claims 1
- 102400000800 Thymosin alpha-1 Human genes 0.000 claims 1
- UVUFIBDXCNFICN-YTUKDDMISA-N [[(2R,3R,4R,5R)-3,4-dihydroxy-4-methyl-5-(11-oxo-3,5,7,9,12-pentazatricyclo[6.4.1.04,13]trideca-1,4,6,8(13)-tetraen-3-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NCC(=O)N3)=C2C3=C1 UVUFIBDXCNFICN-YTUKDDMISA-N 0.000 claims 1
- WKKGEQIYVHERTA-ZCLWBALQSA-N [[(2R,3R,4R,5R)-3,4-dihydroxy-5-(12-iodo-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3I)=C2C3=C1 WKKGEQIYVHERTA-ZCLWBALQSA-N 0.000 claims 1
- UGTQFAADSJDRSS-ZCLWBALQSA-N [[(2R,3R,4R,5R)-3,4-dihydroxy-5-[12-(hydroxyamino)-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl]-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3NO)=C2C3=C1 UGTQFAADSJDRSS-ZCLWBALQSA-N 0.000 claims 1
- LNEZPAJWCWZSLR-KHTZZEJVSA-N [[(2R,3R,4R,5R)-3,4-dihydroxy-5-[12-(methoxyamino)-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl]-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(C2=3)C(NOC)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@]1(C)O LNEZPAJWCWZSLR-KHTZZEJVSA-N 0.000 claims 1
- IRPWNCKXLZNAOT-FTTKWNSESA-N [[(2R,3R,4R,5R)-5-(11-fluoro-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C(F)=C3)=C2C3=C1 IRPWNCKXLZNAOT-FTTKWNSESA-N 0.000 claims 1
- UGTXDEGAFZVXOG-FPOOMLEOSA-N [[(2R,3R,4R,5R)-5-(12-acetamido-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(C2=3)C(NC(=O)C)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@@]1(C)O UGTXDEGAFZVXOG-FPOOMLEOSA-N 0.000 claims 1
- MRLRXQNXOVYHCI-ZQEXUDESSA-N [[(2R,3R,4R,5R)-5-(12-amino-10-oxo-3,5,7,9,11-pentazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)N=C3N)=C2C3=C1 MRLRXQNXOVYHCI-ZQEXUDESSA-N 0.000 claims 1
- ZVWWKBRKHNYVPZ-ZCLWBALQSA-N [[(2R,3R,4R,5R)-5-(12-amino-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3N)=C2C3=C1 ZVWWKBRKHNYVPZ-ZCLWBALQSA-N 0.000 claims 1
- CVWCOPFFHJDDJX-PMXXHBEXSA-N [[(2R,3R,4R,5R)-5-(12-amino-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3-hydroxy-4-methoxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound CO[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3N)=C2C3=C1 CVWCOPFFHJDDJX-PMXXHBEXSA-N 0.000 claims 1
- JSWXEAGVIBIQKU-ZCLWBALQSA-N [[(2R,3R,4R,5R)-5-(12-chloro-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3Cl)=C2C3=C1 JSWXEAGVIBIQKU-ZCLWBALQSA-N 0.000 claims 1
- NSZGCCIJGZZVIO-ZCLWBALQSA-N [[(2R,3R,4R,5R)-5-(12-fluoro-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3F)=C2C3=C1 NSZGCCIJGZZVIO-ZCLWBALQSA-N 0.000 claims 1
- LCFFBOATQVXWEL-ZCLWBALQSA-N [[(2R,3R,4R,5R)-5-(12-hydrazinyl-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxy-4-methyloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C[C@@]1(O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CN=C2NC(=O)C=C3NN)=C2C3=C1 LCFFBOATQVXWEL-ZCLWBALQSA-N 0.000 claims 1
- FFCDTAKRDPJRLR-FRJWGUMJSA-N [[(2R,3S,4R,5R)-5-(12-amino-10-oxo-3,5,7,9-tetrazatricyclo[6.4.1.04,13]trideca-1,4(13),5,8,11-pentaen-3-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate Chemical compound C1=C(C2=3)C(N)=CC(=O)NC2=NC=NC=3N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O FFCDTAKRDPJRLR-FRJWGUMJSA-N 0.000 claims 1
- 125000000852 azido group Chemical group *N=[N+]=[N-] 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 235000013902 inosinic acid Nutrition 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960000329 ribavirin Drugs 0.000 claims 1
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 1
- NZVYCXVTEHPMHE-ZSUJOUNUSA-N thymalfasin Chemical compound CC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O NZVYCXVTEHPMHE-ZSUJOUNUSA-N 0.000 claims 1
- 229960004231 thymalfasin Drugs 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US65746305P | 2005-02-28 | 2005-02-28 | |
| PCT/US2006/007132 WO2006093987A1 (en) | 2005-02-28 | 2006-02-28 | Tricyclic-nucleoside compounds for treating viral infections |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008531704A JP2008531704A (ja) | 2008-08-14 |
| JP2008531704A5 true JP2008531704A5 (OSRAM) | 2009-04-09 |
Family
ID=36570903
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558141A Withdrawn JP2008531703A (ja) | 2005-02-28 | 2006-02-28 | ウイルス感染症の治療のための三環式ヌクレオシドプロドラッグ |
| JP2007558142A Withdrawn JP2008531704A (ja) | 2005-02-28 | 2006-02-28 | ウイルス感染症の治療のための三環式ヌクレオシド化合物 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007558141A Withdrawn JP2008531703A (ja) | 2005-02-28 | 2006-02-28 | ウイルス感染症の治療のための三環式ヌクレオシドプロドラッグ |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7524825B2 (OSRAM) |
| EP (2) | EP1853617A1 (OSRAM) |
| JP (2) | JP2008531703A (OSRAM) |
| KR (2) | KR20070106781A (OSRAM) |
| CN (2) | CN101128474A (OSRAM) |
| AP (2) | AP2007004118A0 (OSRAM) |
| AR (1) | AR058419A1 (OSRAM) |
| AU (2) | AU2006218704A1 (OSRAM) |
| BR (2) | BRPI0607769A2 (OSRAM) |
| CA (2) | CA2597685A1 (OSRAM) |
| EA (2) | EA200701849A1 (OSRAM) |
| HR (2) | HRP20070435A9 (OSRAM) |
| IL (2) | IL184954A0 (OSRAM) |
| MX (2) | MX2007010460A (OSRAM) |
| NO (2) | NO20074613L (OSRAM) |
| TW (1) | TW200640474A (OSRAM) |
| WO (2) | WO2006093987A1 (OSRAM) |
| ZA (1) | ZA200707410B (OSRAM) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2537114C (en) | 2003-08-27 | 2012-10-02 | Biota, Inc. | Tricyclic nucleosides or nucleotides as therapeutic agents |
| US7524825B2 (en) * | 2005-02-28 | 2009-04-28 | Smithkline Beecham Corporation | Tricyclic-nucleoside compounds for treating viral infections |
| US7405204B2 (en) * | 2005-04-25 | 2008-07-29 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US7951789B2 (en) | 2006-12-28 | 2011-05-31 | Idenix Pharmaceuticals, Inc. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| AU2008219622A1 (en) | 2007-02-28 | 2008-09-04 | Conatus Pharmaceuticals, Inc. | Methods for the treatment of liver diseases using specified matrix metalloproteinase (MMP) inhibitors |
| US7964580B2 (en) | 2007-03-30 | 2011-06-21 | Pharmasset, Inc. | Nucleoside phosphoramidate prodrugs |
| WO2009029729A1 (en) * | 2007-08-31 | 2009-03-05 | Genelabs Technologies, Inc. | Amino tricyclic-nucleoside compounds, compositions, and methods of use |
| GB0718575D0 (en) | 2007-09-24 | 2007-10-31 | Angeletti P Ist Richerche Bio | Nucleoside derivatives as inhibitors of viral polymerases |
| TW200942243A (en) | 2008-03-05 | 2009-10-16 | Biocryst Pharm Inc | Antiviral therapeutic agents |
| EP2271351A4 (en) * | 2008-04-03 | 2016-08-31 | Spring Bank Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR TREATING VIRAL INFECTIONS |
| US8173621B2 (en) | 2008-06-11 | 2012-05-08 | Gilead Pharmasset Llc | Nucleoside cyclicphosphates |
| NZ593647A (en) | 2008-12-23 | 2013-08-30 | Gilead Pharmasset Llc | Synthesis of purine nucleosides |
| US8551973B2 (en) | 2008-12-23 | 2013-10-08 | Gilead Pharmasset Llc | Nucleoside analogs |
| SG172359A1 (en) | 2008-12-23 | 2011-07-28 | Pharmasset Inc | Nucleoside phosphoramidates |
| GB0900914D0 (en) * | 2009-01-20 | 2009-03-04 | Angeletti P Ist Richerche Bio | Antiviral agents |
| US8343983B2 (en) * | 2009-03-31 | 2013-01-01 | Arqule, Inc. | Substituted pyrazolo-pyrimidine compounds |
| TWI598358B (zh) | 2009-05-20 | 2017-09-11 | 基利法瑪席特有限責任公司 | 核苷磷醯胺 |
| US8618076B2 (en) | 2009-05-20 | 2013-12-31 | Gilead Pharmasset Llc | Nucleoside phosphoramidates |
| TW201136945A (en) | 2010-03-31 | 2011-11-01 | Pharmasset Inc | Purine nucleoside phosphoramidate |
| PL3290428T3 (pl) | 2010-03-31 | 2022-02-07 | Gilead Pharmasset Llc | Tabletka zawierająca krystaliczny (S)-2-(((S)-(((2R,3R,4R,5R)-5-(2,4-diokso-3,4-dihydropirymidyn-1(2H)-ylo)-4-fluoro-3-hydroksy-4-metylotetrahydrofuran-2-ylo)metoksy)(fenoksy)fosforylo)amino)propanian izopropylu |
| JP2013527145A (ja) | 2010-03-31 | 2013-06-27 | ギリード・ファーマセット・エルエルシー | リン含有活性化剤の立体選択的合成 |
| EP2552203B1 (en) | 2010-04-01 | 2017-03-22 | Idenix Pharmaceuticals LLC. | Compounds and pharmaceutical compositions for the treatment of viral infections |
| PT3042910T (pt) | 2010-11-30 | 2019-04-16 | Gilead Pharmasset Llc | 2'-espiro-nucleósidos para utilização na terapia da hepatite c |
| US9243025B2 (en) | 2011-03-31 | 2016-01-26 | Idenix Pharmaceuticals, Llc | Compounds and pharmaceutical compositions for the treatment of viral infections |
| EP2726610A1 (en) | 2011-06-30 | 2014-05-07 | Stella ApS | Hcv combination therapy |
| WO2013033093A1 (en) * | 2011-08-29 | 2013-03-07 | Biocryst Pharmaceuticals, Inc. | Heterocyclic compounds as janus kinase inhibitors |
| WO2013039920A1 (en) | 2011-09-12 | 2013-03-21 | Idenix Pharmaceuticals, Inc. | Substituted carbonyloxymethylphosphoramidate compounds and pharmaceutical compositions for the treatment of viral infections |
| CA2840242C (en) | 2011-09-16 | 2019-03-26 | Gilead Sciences, Inc. | Methods for treating hcv |
| WO2013056046A1 (en) | 2011-10-14 | 2013-04-18 | Idenix Pharmaceuticals, Inc. | Substituted 3',5'-cyclic phosphates of purine nucleotide compounds and pharmaceutical compositions for the treatment of viral infections |
| US8889159B2 (en) | 2011-11-29 | 2014-11-18 | Gilead Pharmasset Llc | Compositions and methods for treating hepatitis C virus |
| EP2639238A1 (en) * | 2012-03-15 | 2013-09-18 | Universität Bern | Tricyclic nucleosides and oligomeric compounds prepared therefrom |
| AR090699A1 (es) * | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| BR112014029115A8 (pt) | 2012-05-22 | 2018-04-03 | Idenix Pharmaceuticals Inc | Composto, composição farmacêutica, e, uso de um composto ou composição |
| EP2852604B1 (en) | 2012-05-22 | 2017-04-12 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphoramidate prodrugs for hcv infection |
| EP2852605B1 (en) | 2012-05-22 | 2018-01-31 | Idenix Pharmaceuticals LLC | 3',5'-cyclic phosphate prodrugs for hcv infection |
| MX2014014323A (es) | 2012-05-25 | 2015-02-12 | Janssen R & D Ireland | Nucleosidos de espirooxetano de uracilo. |
| WO2014052638A1 (en) | 2012-09-27 | 2014-04-03 | Idenix Pharmaceuticals, Inc. | Esters and malonates of sate prodrugs |
| CN104936970A (zh) | 2012-10-08 | 2015-09-23 | 埃迪尼克斯医药公司 | 用于hcv感染的2′-氯核苷类似物 |
| US10723754B2 (en) | 2012-10-22 | 2020-07-28 | Idenix Pharmaceuticals Llc | 2′,4′-bridged nucleosides for HCV infection |
| WO2014099941A1 (en) | 2012-12-19 | 2014-06-26 | Idenix Pharmaceuticals, Inc. | 4'-fluoro nucleosides for the treatment of hcv |
| KR20200060782A (ko) | 2013-01-31 | 2020-06-01 | 길리애드 파마셋 엘엘씨 | 두 항바이러스 화합물의 병용 제형물 |
| WO2014137926A1 (en) | 2013-03-04 | 2014-09-12 | Idenix Pharmaceuticals, Inc. | 3'-deoxy nucleosides for the treatment of hcv |
| US9339541B2 (en) | 2013-03-04 | 2016-05-17 | Merck Sharp & Dohme Corp. | Thiophosphate nucleosides for the treatment of HCV |
| WO2014160484A1 (en) | 2013-03-13 | 2014-10-02 | Idenix Pharmaceuticals, Inc. | Amino acid phosphoramidate pronucleotides of 2'-cyano, azido and amino nucleosides for the treatment of hcv |
| WO2014165542A1 (en) | 2013-04-01 | 2014-10-09 | Idenix Pharmaceuticals, Inc. | 2',4'-fluoro nucleosides for the treatment of hcv |
| EP3004130B1 (en) | 2013-06-05 | 2019-08-07 | Idenix Pharmaceuticals LLC. | 1',4'-thio nucleosides for the treatment of hcv |
| EP3027636B1 (en) | 2013-08-01 | 2022-01-05 | Idenix Pharmaceuticals LLC | D-amino acid phosphoramidate pronucleotides of halogeno pyrimidine compounds for liver disease |
| EP3650014B1 (en) | 2013-08-27 | 2021-10-06 | Gilead Pharmasset LLC | Combination formulation of two antiviral compounds |
| EP3131914B1 (en) | 2014-04-16 | 2023-05-10 | Idenix Pharmaceuticals LLC | 3'-substituted methyl or alkynyl nucleosides for the treatment of hcv |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4107288A (en) * | 1974-09-18 | 1978-08-15 | Pharmaceutical Society Of Victoria | Injectable compositions, nanoparticles useful therein, and process of manufacturing same |
| PL169273B1 (pl) * | 1990-04-04 | 1996-06-28 | Chiron Corp | skierowanej przeciw wirusowi zapalenia watroby C PL |
| US5145684A (en) * | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| CA2159639A1 (en) | 1993-04-02 | 1994-10-13 | Vincent J. Miles | Method for selective inactivation of viral replication |
| IT1272179B (it) * | 1994-02-23 | 1997-06-16 | Angeletti P Ist Richerche Bio | Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv. |
| US5861267A (en) | 1995-05-01 | 1999-01-19 | Vertex Pharmaceuticals Incorporated | Methods, nucleotide sequences and host cells for assaying exogenous and endogenous protease activity |
| US5981247A (en) | 1995-09-27 | 1999-11-09 | Emory University | Recombinant hepatitis C virus RNA replicase |
| US5759795A (en) | 1996-03-08 | 1998-06-02 | Schering Corporation | Assay for determining inhibitors of ATPase |
| KR20000075983A (ko) | 1997-03-05 | 2000-12-26 | 엘. 데이예를 카렌. | 헤파타이티스 ｃ 바이러스 복제를 선택적으로 저해하는 물질을 확인하기 위한 새로운 스크리닝 방법 |
| WO1998043991A1 (en) * | 1997-04-02 | 1998-10-08 | Amersham Pharmacia Biotech Uk Limited | Tricyclic base analogues |
| EP1037974B1 (en) * | 1997-12-11 | 2007-10-03 | SmithKline Beecham Corporation | Hepatitis c virus ns5b truncated protein and methods thereof to identify antiviral compounds |
| MY164523A (en) | 2000-05-23 | 2017-12-29 | Univ Degli Studi Cagliari | Methods and compositions for treating hepatitis c virus |
| US20030008841A1 (en) | 2000-08-30 | 2003-01-09 | Rene Devos | Anti-HCV nucleoside derivatives |
| HUP0400726A3 (en) | 2001-01-22 | 2007-05-29 | Merck & Co Inc | Nucleoside derivatives as inhibitors of rna-dependent rna viral polymerase |
| WO2003061385A1 (en) * | 2002-01-17 | 2003-07-31 | Ribapharm Inc. | Tricyclic nucleoside library compounds, synthesis, and use as antiviral agents |
| AU2003264038A1 (en) | 2002-08-12 | 2004-02-25 | Bristol-Myers Squibb Company | Combination pharmaceutical agents as inhibitors of hcv replication |
| EP4032897B1 (en) | 2003-05-30 | 2025-01-29 | Gilead Pharmasset LLC | Modified fluorinated nucleoside analogues |
| CA2537114C (en) * | 2003-08-27 | 2012-10-02 | Biota, Inc. | Tricyclic nucleosides or nucleotides as therapeutic agents |
| US7151089B2 (en) | 2003-10-27 | 2006-12-19 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US7157434B2 (en) | 2003-10-27 | 2007-01-02 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US7202223B2 (en) | 2003-10-27 | 2007-04-10 | Genelabs Technologies, Inc. | Nucleoside compounds for treating viral infections |
| US7524825B2 (en) | 2005-02-28 | 2009-04-28 | Smithkline Beecham Corporation | Tricyclic-nucleoside compounds for treating viral infections |
-
2006
- 2006-02-28 US US11/365,321 patent/US7524825B2/en not_active Expired - Fee Related
- 2006-02-28 MX MX2007010460A patent/MX2007010460A/es not_active Application Discontinuation
- 2006-02-28 EA EA200701849A patent/EA200701849A1/ru unknown
- 2006-02-28 AP AP2007004118A patent/AP2007004118A0/xx unknown
- 2006-02-28 AR ARP060100751A patent/AR058419A1/es unknown
- 2006-02-28 KR KR1020077021265A patent/KR20070106781A/ko not_active Withdrawn
- 2006-02-28 BR BRPI0607769-2A patent/BRPI0607769A2/pt not_active IP Right Cessation
- 2006-02-28 WO PCT/US2006/007132 patent/WO2006093987A1/en not_active Ceased
- 2006-02-28 BR BRPI0607770-6A patent/BRPI0607770A2/pt not_active IP Right Cessation
- 2006-02-28 HR HR20070435A patent/HRP20070435A9/xx not_active Application Discontinuation
- 2006-02-28 MX MX2007010463A patent/MX2007010463A/es not_active Application Discontinuation
- 2006-02-28 CN CNA2006800063907A patent/CN101128474A/zh active Pending
- 2006-02-28 CA CA002597685A patent/CA2597685A1/en not_active Abandoned
- 2006-02-28 ZA ZA200707410A patent/ZA200707410B/xx unknown
- 2006-02-28 EA EA200701850A patent/EA200701850A1/ru unknown
- 2006-02-28 KR KR1020077020680A patent/KR20070106767A/ko not_active Withdrawn
- 2006-02-28 WO PCT/US2006/007131 patent/WO2006093986A1/en not_active Ceased
- 2006-02-28 CA CA002597683A patent/CA2597683A1/en not_active Abandoned
- 2006-02-28 AP AP2007004128A patent/AP2007004128A0/xx unknown
- 2006-02-28 JP JP2007558141A patent/JP2008531703A/ja not_active Withdrawn
- 2006-02-28 EP EP06736450A patent/EP1853617A1/en not_active Withdrawn
- 2006-02-28 US US11/365,170 patent/US7534771B2/en not_active Expired - Fee Related
- 2006-02-28 JP JP2007558142A patent/JP2008531704A/ja not_active Withdrawn
- 2006-02-28 CN CNA2006800063894A patent/CN101142226A/zh active Pending
- 2006-02-28 HR HR20070436A patent/HRP20070436A2/xx not_active Application Discontinuation
- 2006-02-28 EP EP06736451A patent/EP1853618A1/en not_active Withdrawn
- 2006-02-28 AU AU2006218704A patent/AU2006218704A1/en not_active Abandoned
- 2006-02-28 AU AU2006218705A patent/AU2006218705A1/en not_active Abandoned
- 2006-03-01 TW TW095106861A patent/TW200640474A/zh unknown
-
2007
- 2007-07-31 IL IL184954A patent/IL184954A0/en unknown
- 2007-07-31 IL IL184955A patent/IL184955A0/en unknown
- 2007-09-11 NO NO20074613A patent/NO20074613L/no not_active Application Discontinuation
- 2007-09-27 NO NO20074915A patent/NO20074915L/no not_active Application Discontinuation
-
2009
- 2009-03-31 US US12/415,335 patent/US20090253648A1/en not_active Abandoned
- 2009-03-31 US US12/415,286 patent/US20090208457A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008531704A5 (OSRAM) | ||
| AU2009293493B2 (en) | Combination of HCV NS3 protease inhibitor with interferon and ribavirin | |
| RU2011139180A (ru) | Комбинация нуклеозидного ингибитора полимеразы и макроциклического ингибитора протеазы и ее применение для лечения гепатита с, фиброза печени и нарушенной печеночной функции | |
| JP2013521279A5 (OSRAM) | ||
| JP2016503800A5 (OSRAM) | ||
| JP2015525220A5 (OSRAM) | ||
| JP2008518943A5 (OSRAM) | ||
| JP2013514359A5 (OSRAM) | ||
| RU2006124594A (ru) | Ингибиторы сериновой протеазы ns3/ns4а вируса гепатита с | |
| EP2341065A3 (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4a protease | |
| JP2012512169A5 (OSRAM) | ||
| JP2012504632A5 (OSRAM) | ||
| WO2004002422A3 (en) | 2’-c-methyl-3’-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| JP2015512860A5 (OSRAM) | ||
| JP2012504126A5 (OSRAM) | ||
| WO2005077969A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| TR201906767T4 (tr) | Modifiye florlanmış nükleosit analogları. | |
| TW200500373A (en) | 2'-c-methyl-3'-o-l-valine ester ribofuranosyl cytidine for treatment of flaviviridae infections | |
| TW200510391A (en) | Inhibitors of serine proteases, particularly HCV NS3-NS4A protease | |
| AR021876A1 (es) | Terapia de combinacion para vhc por induccion de ribavirina - interferon alfa pegilado | |
| WO2005037860A3 (en) | Inhibitors of serine proteases, particularly hcv ns3-ns4a protease | |
| RU2008152171A (ru) | Новые ингибиторы вирусной репликации гепатита с | |
| JP2012513479A5 (OSRAM) | ||
| JP2014505045A (ja) | Ｈｃｖを処置するための組合せ | |
| EP2374464A3 (en) | HCV N3S-NS4A protease inhibition |